1. Loss of bone mineral density and secondary hyperparathyroidism are complications of autologous stem cell transplantation
- Author
-
Elmo Mannarino, Benedetta Pallone, Paolo Sportoletti, Mauro Di Ianni, Roberto Ria, Anna Maria Scarponi, Antonio Tabilio, Angelo Vacca, Franca Falzetti, Michele Cimminiello, Franco Dammacco, Stelvio Ballanti, and Cristiana Gasbarrino
- Subjects
Adult ,Male ,musculoskeletal diseases ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Osteoporosis ,Antineoplastic Agents ,Transplantation, Autologous ,Bone and Bones ,Bone remodeling ,Autologous stem-cell transplantation ,Bone Density ,Humans ,Medicine ,Aged ,Bone mineral ,Chemotherapy ,Hyperparathyroidism ,business.industry ,Hematology ,Middle Aged ,musculoskeletal system ,medicine.disease ,Surgery ,Osteopenia ,Bone Diseases, Metabolic ,Oncology ,Hematologic Neoplasms ,Female ,Secondary hyperparathyroidism ,business ,Stem Cell Transplantation - Abstract
Patients who underwent autologous stem cell transplantation (ASCT) are prone to decreased bone mineral density (BMD). We measured BMD in 180 patients who underwent ASCT for hematologic malignancies. Patients were evaluated with a median of 6.2 years after ASCT. Twenty patients who received only chemotherapy were evaluated as controls. The loss of bone mass was greater during the first year after ASCT, since majority of patients recover BMD and normalize bone turnover markers during the following years. After ASCT, over half of the patients show osteopenia or osteoporosis independent of the sex. According to the results of other groups, our results emphasize the potential usefulness of antiresorptive agents to prevent or treat post-ASCT osteopenia or osteoporosis, and the importance of the measurement of BMD as an integral component to the follow-up of ASCT.
- Published
- 2007